Skip to content
Adam Torkildson – Lifestyle
Author:
ELI LILLY AND COMPANY
Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
July 23, 2026
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
July 22, 2026
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
July 16, 2026
/C O R R E C T I O N — Eli Lilly and Company/
July 9, 2026
Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
July 9, 2026
Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
June 26, 2026
What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
June 25, 2026
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
June 24, 2026
Lilly declares third-quarter 2026 dividend
June 22, 2026
Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
June 14, 2026
1
2
3
…
5
Next Page
→